SNP-Based Statin Response Prediction and Cardiovascular Risk Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective genetic markers to predict individual responsiveness to statins and identify those at risk for cardiovascular diseases such as coronary heart disease and stroke, leading to inadequate treatment and prevention strategies.
Innovation Solution
Identification of specific single nucleotide polymorphisms (SNPs) associated with variability in response to statins, which can be used to develop diagnostic and prognostic reagents and therapeutic agents for predicting individual responses to statin treatment and assessing cardiovascular disease risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used for cardiovascular disease treatment and prevention, then general population approaches are applied, but individual responsiveness to statins cannot be predicted and treatment efficacy is insufficient
Solution Approach 1:
The invention segments the population into distinct genetic subgroups based on SNP profiles (e.g., CYP3A5*3 polymorphisms). By dividing the homogeneous treatment approach into heterogeneous genetically-defined groups, the patent enables precision medicine strategies where treatment decisions are tailored to individual genetic characteristics, thereby improving both measurement precision of response prediction and reliability of treatment outcomes
Solution Approach 2:
The invention changes the parameter used for treatment selection from general clinical factors to specific genetic parameters (SNP genotypes). By identifying and measuring specific genetic polymorphisms such as CYP3A5*3, the patent transforms the approach from empirical treatment to genetically-informed treatment, enhancing the ability to predict individual statin response and improve treatment effectiveness
2Adaptability or versatility
If genetic markers are not used, then treatment decisions are made without genetic information, but personalized treatment approaches cannot be implemented
Solution Approach 1:
The invention performs preliminary genetic testing to identify SNP profiles (such as CYP3A5*3 polymorphisms) before making treatment decisions. By obtaining genetic information in advance, the patent enables clinicians to adapt treatment approaches based on individual genetic characteristics, preventing the loss of valuable predictive information and allowing personalized medicine strategies to be implemented from the outset
Solution Approach 2:
The invention introduces genetic markers (SNPs) as intermediary variables that mediate between statin treatment and clinical outcomes. These genetic markers serve as informative intermediaries that carry information about individual susceptibility and response, enabling the translation of genetic variation into actionable treatment decisions without directly measuring the complex biological pathways involved
3Reliability
If specific SNPs are identified for statin response prediction, then personalized treatment can be achieved, but additional diagnostic testing and genetic analysis are required
Solution Approach 1:
The invention extracts and focuses on specific, high-value genetic markers (such as CYP3A5*3 polymorphisms) that have been shown to be strongly associated with statin response. By selecting and isolating these key SNPs rather than analyzing the entire genome or numerous low-value markers, the patent achieves reliable prediction of treatment response while minimizing diagnostic complexity and testing requirements
Solution Approach 2:
The invention identifies SNPs that serve multiple functions: they predict statin response, indicate cardiovascular disease risk, and guide treatment selection. By finding genetic markers with multiple clinical applications, the patent reduces the need for separate diagnostic tests for different purposes, thereby improving prediction reliability without proportionally increasing diagnostic complexity
Data Source
AI summary
The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents and kits for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents and kits for their detection.